Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Still Rules Immuno-Oncology, But For How Long?

Executive Summary

At $920m, sales for Opdivo still overshadow competitors, but market dynamics are set to change with introduction of Merck's Keytruda in first-line lung cancer and Roche's Tecentriq in second-line lung.


Related Content

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
Wait For Me: AstraZeneca’s Durvalumab Gets Its Turn At The FDA
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Bristol Stresses Cost Control Despite Strong Earnings Quarter
AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS
Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts